Skip to main content

Table 3 Stratified analysis of the relationships between AKAP6 polymorphisms and glioma risk

From: Impact of AKAP6 polymorphisms on Glioma susceptibility and prognosis

SNP IDModelsOR (95%CI)pOR (95%CI)p
Age ≤ 40>  40
rs2239647Allele1.20 (0.92–1.57)0.1711.17 (0.89–1.54)0.273
Homozygote(AA)1.68 (0.87–3.24)0.1232.60 (1.23–5.51)0.012
Heterozygote(CA)1.19 (0.83–1.71)0.3470.82 (0.57–1.18)0.281
Dominant1.26 (0.89–1.78)0.1870.98 (0.70–1.39)0.925
Recessive1.56 (0.82–2.95)0.1742.83 (1.36–5.89)0.006
Additive1.25 (0.95–1.64)0.1071.17 (0.89–1.54)0.254
Gender MaleFemale
rs2145587Allele1.06 (0.84–1.33)0.6331.28 (0.98–1.68)0.065
Homozygote(AA)1.16 (0.71–1.90)0.5531.40 (0.77–2.53)0.266
Heterozygote(CA)1.00 (0.70–1.43)0.9981.62 (1.10–2.38)0.016
Dominant1.04 (0.74–1.45)0.8371.57 (1.08–2.27)0.017
Recessive1.16 (0.74–1.82)0.5141.08 (0.62–1.87)0.794
Additive1.06 (0.84–1.34)0.6251.30 (0.99–1.71)0.060
rs2239647Allele1.22 (0.94–1.58)0.1301.14 (0.86–1.51)0.374
Homozygote(AA)2.42 (1.21–4.87)0.0031.48 (0.75–2.89)0.256
Heterozygote(GA)0.94 (0.67–1.32)0.7141.02 (0.70–1.50)0.909
Dominant1.08 (0.78–1.50)0.6271.09 (0.76–1.57)0.630
Recessive2.49 (1.25–4.93)0.0091.46 (0.76–2.80)0.253
Additive1.22 (0.94–1.57)0.1351.13 (0.86–1.50)0.384
Classification Astroglioma patients VS Healthy controls
rs2239647Allele1.18 (0.96–1.45)0.106  
Homozygote(AA)1.90 (1.15–3.15)0.012  
Heterozygote(CA)0.98 (0.75–1.29)0.900  
Dominant1.10 (0.85–1.42)0.485  
Recessive1.92 (1.17–3.13)0.009  
Additive1.19 (0.97–1.45)0.098  
  1. SNP single nucleotide polymorphism, OR odds ratio, 95% CI 95% confidence interval
  2. p values were calculated by logistic regression analysis with adjustments for age and gender
  3. Bold values indicate statistical significance (p < 0.05)